PURPOSE: The aim of this work was to investigate cardiorespiratory fitness in breast cancer patients at different time points of anti-cancer treatment. PATIENTS AND METHODS: Non-metastatic breast cancer patients (n = 222, mean age 55 years) were categorized into four subgroups according to their treatment status. Cardiopulmonary exercise testing (CPET) was used to measure patients' cardiorespiratory fitness, including oxygen delivery and metabolic muscle function. Testing was performed by bicycle ergometry, and maximal oxygen uptake (VO2peak) was measured. Heart rate during exercise at 50 watts (HR50) was assessed as a cardiocirculatory parameter and ventilatory threshold (VT) was used as an indicator of the O2 supply to muscle. Analysis of covariance was used to estimate the impact of different cancer treatments on cardiorespiratory fitness with adjustment for clinical factors. RESULTS:Submaximal measures were successfully assessed in 220 (99%) and 200 (90%) patients for HR50 and VT, while criteria for maximal exercise testing were met by 176 patients (79%), respectively. The mean VO2peak was 20.6 ± 6.7 ml/kg/min, mean VT 10.7 ± 2.9 ml/min/kg and mean HR50 112 ± 16 beats/min. Chemotherapy was significantly associated with decreased VO2peak, with significantly lower adjusted mean VO2peak among patients post adjuvant chemotherapy compared to patients with no chemotherapy or those who just started chemotherapy regime (all p < 0.01). Patients post adjuvant chemotherapy reached only 63% of the VO2peak level expected for their age- and BMI-category (mean VO2peak 15.5 ± 4.8 ml/kg/min). Similarly, HR50 was significantly associated with treatment. However, VT was not associated with treatment. CONCLUSION:Breast cancer patients have marked and significantly impaired cardiopulmonary function during and after chemotherapy. Hereby, chemotherapy appears to impair cardiorespiratory fitness by influencing the oxygen delivery system rather than impacting metabolic muscle function. Our findings underline the need of exercise training in breast cancer patients to counteract the loss of cardiorespiratory fitness during the anti-cancer treatment.
RCT Entities:
PURPOSE: The aim of this work was to investigate cardiorespiratory fitness in breast cancerpatients at different time points of anti-cancer treatment. PATIENTS AND METHODS: Non-metastatic breast cancerpatients (n = 222, mean age 55 years) were categorized into four subgroups according to their treatment status. Cardiopulmonary exercise testing (CPET) was used to measure patients' cardiorespiratory fitness, including oxygen delivery and metabolic muscle function. Testing was performed by bicycle ergometry, and maximal oxygen uptake (VO2peak) was measured. Heart rate during exercise at 50 watts (HR50) was assessed as a cardiocirculatory parameter and ventilatory threshold (VT) was used as an indicator of the O2 supply to muscle. Analysis of covariance was used to estimate the impact of different cancer treatments on cardiorespiratory fitness with adjustment for clinical factors. RESULTS: Submaximal measures were successfully assessed in 220 (99%) and 200 (90%) patients for HR50 and VT, while criteria for maximal exercise testing were met by 176 patients (79%), respectively. The mean VO2peak was 20.6 ± 6.7 ml/kg/min, mean VT 10.7 ± 2.9 ml/min/kg and mean HR50 112 ± 16 beats/min. Chemotherapy was significantly associated with decreased VO2peak, with significantly lower adjusted mean VO2peak among patients post adjuvant chemotherapy compared to patients with no chemotherapy or those who just started chemotherapy regime (all p < 0.01). Patients post adjuvant chemotherapy reached only 63% of the VO2peak level expected for their age- and BMI-category (mean VO2peak 15.5 ± 4.8 ml/kg/min). Similarly, HR50 was significantly associated with treatment. However, VT was not associated with treatment. CONCLUSION:Breast cancerpatients have marked and significantly impaired cardiopulmonary function during and after chemotherapy. Hereby, chemotherapy appears to impair cardiorespiratory fitness by influencing the oxygen delivery system rather than impacting metabolic muscle function. Our findings underline the need of exercise training in breast cancerpatients to counteract the loss of cardiorespiratory fitness during the anti-cancer treatment.
Authors: Friederike Scharhag-Rosenberger; Rea Kuehl; Oliver Klassen; Kai Schommer; Martina E Schmidt; Cornelia M Ulrich; Joachim Wiskemann; Karen Steindorf Journal: J Cancer Surviv Date: 2015-02-26 Impact factor: 4.442
Authors: Martine Extermann; Christiaan Leeuwenburgh; Laila Samiian; Marina Sehovic; Jinze Xu; Christopher Cubitt; Paul B Jacobsen; Marco Pahor; Stephen R Grobmyer; Todd M Manini Journal: J Geriatr Oncol Date: 2016-10-13 Impact factor: 3.599
Authors: Chelsea Anderson; Dale P Sandler; Clarice R Weinberg; Kevin Houck; Minal Chunduri; M Elizabeth Hodgson; Susan A Sabatino; Mary C White; Juan L Rodriguez; Hazel B Nichols Journal: Breast Date: 2017-02-27 Impact factor: 4.380
Authors: Dorothea Clauss; Christine Tjaden; Thilo Hackert; Lutz Schneider; Cornelia M Ulrich; Joachim Wiskemann; Karen Steindorf Journal: Support Care Cancer Date: 2017-04-17 Impact factor: 3.603
Authors: Tom Møller; Christian Lillelund; Christina Andersen; Kira Bloomquist; Karl Bang Christensen; Bent Ejlertsen; Lone Nørgaard; Liza Wiedenbein; Peter Oturai; Ulla Breitenstein; Lis Adamsen Journal: BMJ Open Sport Exerc Med Date: 2015-10-23
Authors: Oliver Klassen; Martina E Schmidt; Cornelia M Ulrich; Andreas Schneeweiss; Karin Potthoff; Karen Steindorf; Joachim Wiskemann Journal: J Cachexia Sarcopenia Muscle Date: 2016-11-28 Impact factor: 12.910
Authors: S Schwarz; O Prokopchuk; K Esefeld; S Gröschel; J Bachmann; S Lorenzen; H Friess; M Halle; M E Martignoni Journal: BMC Cancer Date: 2017-02-14 Impact factor: 4.430
Authors: Amy A Kirkham; Mark J Haykowsky; Rhys I Beaudry; Justin G Grenier; John R Mackey; Edith Pituskin; D Ian Paterson; Richard B Thompson Journal: Sci Rep Date: 2021-07-07 Impact factor: 4.379